ストックスクリーナーアプリを入手
4.27
1.61%
-0.07
アフターアワーズ：
4.26
-0.010
-0.23%
前日終値:
$4.34
開ける：
$4.36
24時間の取引高:
513.09K
Relative Volume:
0.58
時価総額：
$276.26M
収益：
$500
当期純損益:
$-54.44M
株価収益率:
-3.6627
EPS:
-1.1658
ネットキャッシュフロー:
$-49.91M
1週間 パフォーマンス:
-4.69%
1か月 パフォーマンス:
-18.36%
6か月 パフォーマンス:
-19.74%
1年 パフォーマンス:
-46.63%
1日の値動き範囲:
$4.255
$4.40
1週間の範囲:
$4.20
$4.665
52週間の値動き範囲:
$3.86
$8.48
Immuneering Corp Stock (IMRX) Company Profile
名前
Immuneering Corp
セクター
電話
617-500-8080
住所
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.27 | 276.26M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-31 | 開始されました | Leerink Partners | Outperform |
| 2024-12-13 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-15 | 繰り返されました | Needham | Buy |
| 2024-03-15 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 開始されました | Needham | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-04-19 | アップグレード | Mizuho | Neutral → Buy |
| 2023-04-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 開始されました | Mizuho | Neutral |
| 2023-02-03 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 開始されました | Chardan Capital Markets | Buy |
| 2022-04-01 | 開始されました | Oppenheimer | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Immuneering Corp (IMRX) 最新ニュース
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering to Present at the ESMO Congress 2026 - The Manila Times
A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan
Immuneering Corporation(NasdaqGM: IMRX) added to S&P Global BMI Index - marketscreener.com
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
Immuneering at H.C. Wainwright conference: pancreatic cancer push By Investing.com - Investing.com Nigeria
Immuneering at H.C. Wainwright conference: pancreatic cancer push - Investing.com
Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus - Investing.com Canada
Immuneering Stock (IMRX) Opinions on Pancreatic Cancer Drug Presentation - Quiver Quantitative
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference - Quiver Quantitative
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival - The Manila Times
84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan
Immuneering to Participate in Upcoming Investor Conferences - Yahoo Finance
H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential - Investing.com India
Immuneering comments on FDA pancreatic cancer drug approval By Investing.com - Investing.com India
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - barchart.com
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
HC Wainwright Initiates Immuneering at Buy With $14 Price Target - Yahoo Finance
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
Immuneering Corp (IMRX) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):